Amplified Sciences is a molecular diagnostics company unlike other diagnostics companies due to their ultra-sensitive molecular sensing technology with composition of matter IP exclusively licensed from Purdue University. The technology is disease state agnostic, can detect to the single molecule level, scales easily to point of care, and provides a very favorable cost structure for their platform of reagents. The first application – early detection of pancreatic cancer – is a clinical stage assay that will quickly prove the investment thesis due to large unmet medical need and a favorable reimbursement path. The company has raised total of $2M of funding, clinical testing data were presented at ASCO 2022 and published in a peer reviewed journal, and $235k of RUO revenue secured. The lead assay is optimized and technically validated, global IP issued, and thought leader clinicians have been secured at UCSF, UPMC, and IU Simon Cancer Center. Current Seed round (closed in early 2021) will enable technical validation and clinical testing of the PanCystPro product and position the company for entry into a commercializable LDT. Closure of a Series A in late 2022 will enable regulatory CLIA approval and launch in 2023, and the scale of a suite of LDT and 510k assays.